A Phase 3 Multi-Center Randomized Double-Blind Trial to Evaluate The Efficacy and Safety of Aficamten Compared To Placebo in Adults with Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy

Brief description of study

The purpose of this research study is to compare the effects of aficamten and placebo on health status and exercise capacity in participants with non-obstructive hypertrophic cardiomyopathy (nHCM). The safety and tolerability of aficamten at different, increasing dose levels will also be studied. The effectiveness of aficamten and placebo will be compared by measuring your ability to exercise, heart failure symptoms, and the structure of your heart.

Aficamten is an oral investigational medicine designed to reduce excessive contraction of your heart muscle that is the root cause of nHCM. “Investigational” means that this medicine is not approved by United States Food and Drug Administration (FDA) but is available in research studies like this one.


Clinical Study Identifier: s23-01100
Principal Investigator: Mark V. Sherrid.


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.